Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Shiro Soga

Yukimasa Shiotsu

Shiro Akinaga

Yutaka Kanda

Chikara Murakata

Nobuyoshi Amishiro

Shinji Nara

Yoji Ino

Takayuki Nakashima

Harumi Ogawa

Tadakazu Akiyama

Mayumi Miyata

Hiroshi Nakagawa

Jiro Kajita

Jun-ichi Saito

Kenji Shibata

Motoo Yamasaki

Koji Yamada

Toshiyuki Suzawa

Takeo Tanaka

Tatsuhiro Ogawa

Yushi Kitamura

Rieko Nakatsu

Shinji Kyowa Hakko Kogyo Co Ltd Nara

Yutaka Kyowa Hakko Kogyo Co Ltd Kanda

Hiroshi Kyowa Hakko Kogyo Co Ltd Nakagawa

Takayuki Kyowa Hakko Kogyo Co Ltd Nakashima

Shiro Kyowa Hakko Kogyo Co Ltd Akinaga

Jiro Kyowa Hakko Kogyo Co Ltd Kajita

Yukimasa Kyowa Hakko Kogyo Co Ltd Shiotsu

Jun-Ichi Kyowa Hakko Kogyo Co Ltd Saito

The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONRRor the like; Rrepresents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; Rand R, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and Rand R, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Hsp90 family protein inhibitors

(wherein n is an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic-alkyl, substituted or unsubstituted aryl, &#x2014;CONRR, &#x2014;NRR, etc.; Rrepresents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, etc.; Rand Rmay be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, etc.) Provided are an Hsp90 family protein inhibitor comprising, as an active ingredient, a benzene derivative of formula (I) or a prodrug thereof or a pharmaceutically-acceptable salt thereof, etc.

The present invention provides peptides represented by the following formula (A):wherein Q represents a physiologically active peptide moiety; X each represents the same or different &#x3b1;-amino acid residue; M represents Gly or Cys; m represents an integer of from 5 to 8; and n represents an integer of from 0 to 3, or their pharmaceutically acceptable salts thereof. The peptides of the present invention have higher stability and/or higher activity than physiologically active linear peptides to which no cyclic peptide is bonded.

Peptides

Radicicol derivatives

Radioicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof:

Radicicol derivatives represented by the following formula (I) having tyrosine kinase inhibition activity or pharmacologically acceptable salts thereof:

Growing community of inventors

Rockville, MD, United States of America

Shiro Soga